Preface

All of us use pharmaceuticals for ourselves or for our pets, in husbandry, in agriculture or in aquaculture. But who knows what will happen to the compounds after their administration or use? Are they distributed in the environment or are they eliminated beforehand? What are the possible effects and risks for humans and the environment in connection with the emission of pharmaceuticals into the environment? Pharmaceuticals, diagnostic aids as well as disinfectants used in medicine enter municipal sewage and the aquatic environment. Drugs and growth promoters used in veterinary medicine and husbandry are excreted by animals and emitted into soil via manure or can be part of the runoff from soils after heavy rain fall, which then passes into surface water. Drugs used in aquaculture are passed directly into surface water. Some, such as X-ray contrast media, are excreted completely unchanged, while others are metabolised either into metabolites, which are still active or inactive metabolites. Outdated medications or their remnants are sometimes disposed of down household drains or as (household) waste. The fate, occurrence and effects of pharmaceuticals in the aquatic and terrestrial environment is still mainly unknown.

The disposal of pharmaceuticals in the environment means that a huge number of different substances in different amounts, products and modes of action have to be considered. Therefore, it is difficult to obtain an appropriate overview on the ongoing research. It is even more difficult to identify the most important questions for a systematic approach. The information available is still scarce and not sufficient for sound assessment and decision-making. For this reason, the European Science Foundation (ESF), located in Strasbourg (France), commissioned the workshop "Pharmaceuticals in the Environment." It was held in July 1999 in Freiburg (Germany). The core of the book consists of issues discussed and explored in depth during this workshop. Some other authors, not present at the workshop, have been added.

The book does not claim to give a complete review of the state of the art related to pharmaceuticals in the environment. There is a lot of literature, symposia, international networking and research organising on EDSs. This is still lacking for pharmaceuticals other than hormones. This book gives a short review of the fate, occurence and effects of pharmaceuticals using examples of some typical compounds to highlight the most important questions and issues related to pharmaceuticals into the environment. Input, occurence, fate and effects as well as the possible risks and their assessment are addressed. The book also gives an introduction to this new field of environmental chemistry, ecotoxicology and environmental hygiene.

This book would not have been realised without the workshop "Pharmaceuticals in the Environment" commissioned by the European Science Foundation (ESF). Dr. A. Moth-

X Preface

Wiklund and her team from the Life and Environment Standing Commitee (LESC) at the ESF always gave good support whenever necessary. All the participants of the workshop contributed to the lively discussions and the identification of the important questions of research in the future. The contributors to this volume were very patient with the editor. The workshop and the book would have not been realised without the support of the director of the Institute of Environmental Medicine and Hospital Epidemiology at the Freiburg University Hospital, Prof. Dr. med. Franz Daschner, and of all my co-workers in the field of pharmaceuticals in the environment. Tina Kümpel and Birgit Stadel helped with the manuscripts. Dr. Witschel from Springer Verlag (Heidelberg) created the opportunity to publish this book. Special thanks to my wife and my children for their encouragement and their support.

Thank you!

Klaus Kümmerer Freiburg, January 2001

Contents

1	Introduction: Pharmaceuticals in the Environment 1
1.1	Historical Background
1.2	Use
1.3	Legislation
1.4	Occurrence: Evidence of Drugs in the Aquatic Environment
1.5	Fate
1.6	Effects
1.7	Risk 1
1.8	Conclusion
	References
Par	t I Emission, Occurrence, Fate and Effects
2	Effects on Pharmaceuticals in the Environment –
	an Overview and Principle Considerations 1
2.1	Occurrence of Pharmaceuticals in the Environment
2.2	Environmental Effects of Pharmaceuticals on Organisms and
	Ecosystems
	2.2.1 Risk Assessment
	2.2.2 Use of Pharmaceuticals, Mode of Action and/or Adverse Side
	Effects in Mammals as a Basis for Studying the Potential
	Environmental Impacts
	2.2.3 Carbamazepine: An Example for Investigative Environmental
	Toxicology Using Mammalian Data
2.3	A Final Perspective
	References 1
3	Environmental Loads and Detection of Pharmaceuticals in Italy 1
3.1	Introduction1
3.2	Experimental
	3.2.1 Environmental Loads of Drugs for Human Use
	3.2.2 Environmental Loads of Drugs for Veterinary Use
	3.2.3 Presence and Persistence of Drugs as Environmental
	Contaminants 1
	3.2.4 Selection of Pharmacological Substances to Be Measured
	in the Environment

XII Contents

3.3	3.2.5 HPLC-Electrospray MS-MS Method for Measuring Pharmacological Substances in Environmental Media Preliminary Results and Prospects Acknowledgements References
4	Emission and Biodegradability of Pharmaceuticals, Contrast Media, Disinfectants and AOX from Hospitals
4.1	Cytostatic Agents
4.2	Antibiotics
4.3	Disinfectants
4.4	Heavy Metals
	4.4.1 Platinum
	4.4.2 Mercury
	4.4.3 Gadolinium
4.5	AOX (Adsorbable Organic Halogen Compounds)
4.6	Iodised X-Ray Contrast Media
4.0	References
	References
5	Emissions from Clinical-Chemical Laboratories
5.1	Introduction
5.2	Issues
-	Ecological Aspects of Instrument Runoffs and Test Reagents
5.3	Summary and Outlook
5.4	References
	References
6	Pharmaceuticals in the Environment:
U	Focus on 17α -ethinyloestradiol
6.1	Introduction
6.1 6.2	
0.2	Materials and Methods
	6.2.1 Chemicals, Glass Material and Water
	6.2.2 Colony Counts
	6.2.3 Analytical Methods
	6.2.4 Biodegradation Experiments:
	Biological Material and Experimental Design
	6.2.5 Activated Sludge: Zahn-Wellens Test (ISO 9888)
	6.2.6 Toxicity Evaluation: Nitrox
	6.2.7 Statistical Analyses
6.3	Results
6.4	Discussion
	Acknowledgements
	References
7	What Do We Know about Antibiotics in the Environment?
7. 1	Introduction
7.2	Emission and Occurrence of Antibiotics in the Environment
-	73.1 Wastawatar Surface Water and Groundwater

Contents XIII

		Т
	7.2.2 Soil and Sediment	1
7.3	Fate of Antibiotics in the Environment	
, .	7.3.1 Biodegradation	1
	7.3.2 Photodegradation and Hydrolysis	
	7.3.3 Complex Formation and Adsorption	
7.4	Effects on the Environment	
	7.4.1 Wastewater and Sewage System	
	7.4.2 Surface Water	
	7.4.3 Soil and Sediments	
7. 5	Conclusion	
	Acknowledgements References	
	References	1
8	Antibiotics in the Environment:	
	Zinc Bacitracin – Environmental Toxicity and Breakdown	1
8.1	General Introduction	
8.2	Zinc Bacitracin	
	8.2.1 Structure and Pharmacology	
	8.2.2 ZB and Environmental Fate	
8.3	Conclusions	
	References	1
9	Pharmaceutical Residues in the Aquatic Environment and	
	their Significance for Drinking Water Production	1
9.1	Introduction	1
9.2	Pharmaceuticals in the Aquatic Environment	1
9.3	Pharmaceuticals in Sewage Water Treatment	
9.4	Pharmaceuticals in Drinking Water Treatment	
9.5	Future Research Needs	
	References	1
10	Pharmaceuticals as Environmental Contaminants:	
	Modelling Distribution and Fate	1
10.1	Introduction	1
10.2	Data Evaluation	1
10.3	Generic Model	1
	Regional Model	
	Site Specific Models	
10.6	Discussion and Conclusions	
	References	1
Part	II Risk Assessment	1
11	Risk Assessment of Organic Xenobiotics in the Environment	1
11.1	Introduction	
11.2	Definitions	1
11 2	Global Approach	1

XIV Contents

	11.3.1 Assessment Endpoints	1
	11.3.2 Determination of Exposures and Effects	
	- <u>-</u>	1
	11.3.3 Determination of Acceptable Level in Environment – Example	
	of an Application: Determination of Safe Levels for PAHs in	
	Urban Sewage Sludges	
	Specific Approach	
	Conclusion: Application to Pharmaceuticals	
Refe	erences	1
12	Ecotoxicological Evaluation of Pharmaceuticals	
12.1	Introduction	1
12.2	Legal Situation	
	12.2.1 Germany	1
	12.2.2 European Union	
	12.2.3 United States of America	
	12.2.4 International Harmonisation	
12 2	Environmental Risk Assessment	
12.5	12.3.1 General ERA Principles	
	12.3.2 ERAs for Selected Medicinal Products	
10.4	Proposal for an ERA Procedure for Medicinal Products	
12.4	12.4.1 Hazard Identification	1
	12.4.2 Exposure Analysis	
	12.4.3 Effect Analysis	
	12.4.4 Risk Characterisation	
	12.4.5 Risk Management	
	Comparison of Various ERA Proposals	
12.6	Discussion and Recommendations	1
Refe	erences	1
13	Worst-Case Estimations of Predicted Environmental Soil	
	Concentrations (PEC) of Selected Veterinary Antibiotics	
	and Residues Used in Danish Agriculture	
13.1	Introduction	1
13.2	Models	1
	13.2.1 Grazing Animals on Arable Land	
	13.2.2 Soil Amended with Manure from Stabled Animals	
	13.2.3 Modelled Scenarios	
13.3		
13.3	13.3.1 Scenario A	
	13.3.2 Scenario B and C	
	Conclusion	
	nowledgements	
Kete	erences	1
14	Regulatory and Methodological Aspects Concerning the	_
	Risk Assessment for Medicinal Products; Need for Research	1
1 / 1	Introduction	-1

		_
14.2	14.1.1 Risk Management	1
	14.2.2 Residues of Pharmaceuticals in Dung Human Pharmaceuticals in Surface Water Results and Discussion References	1 1
15	A Data-based Perspective on the Environmental Risk Assessment	_
13	of Human Pharmaceuticals I – Collation of Available Ecotoxicity	
	Data	1
15.1	Introduction	1
	Methods	
15.3	Results	
	15.3.1 Acute Ecotoxicity Data	
	15.3.2 Chronic Ecotoxicity Data	
	Discussion	
15.5	Conclusions	
	References Appendix	
	Appendix	1
16	A Data Based Perspective on the Environmental Risk Assessment	
. •	of Human Pharmaceuticals II – Aquatic Risk Characterisation	1
16.1	Introduction	
	Methodology	
	Results	
16.4	Discussion	1
16.5	Conclusions	1
	References	1
17	A Data Based Perspective on the Environmental Risk Assessment	
	of Human Pharmaceuticals III – Indirect Human Exposure	
17.1	of Human Pharmaceuticals III – Indirect Human Exposure Introduction	1
17.2	of Human Pharmaceuticals III - Indirect Human Exposure Introduction Methodology	1
17.2 17.3	of Human Pharmaceuticals III - Indirect Human Exposure Introduction Methodology Results	1 1
17.2 17.3 17.4	of Human Pharmaceuticals III – Indirect Human Exposure Introduction Methodology Results Discussion	1 1 1
17.2 17.3	of Human Pharmaceuticals III - Indirect Human Exposure Introduction Methodology Results Discussion Conclusions	1 1 1 1
17.2 17.3 17.4	of Human Pharmaceuticals III – Indirect Human Exposure Introduction Methodology Results Discussion	1 1 1 1
17.2 17.3 17.4	of Human Pharmaceuticals III – Indirect Human Exposure Introduction Methodology Results Discussion Conclusions References	1 1 1 1
17.2 17.3 17.4 17.5	of Human Pharmaceuticals III - Indirect Human Exposure Introduction Methodology Results Discussion Conclusions	1 1 1 1 1
17.2 17.3 17.4 17.5	of Human Pharmaceuticals III - Indirect Human Exposure Introduction Methodology Results Discussion Conclusions References The ECO-SHADOW Concept - A New Way of Following Environmental Impacts of Antimicrobials General Introduction	1 1 1 1 1 1
17.2 17.3 17.4 17.5 18 18.1 18.2	of Human Pharmaceuticals III - Indirect Human Exposure Introduction Methodology Results Discussion Conclusions References The ECO-SHADOW Concept - A New Way of Following Environmental Impacts of Antimicrobials General Introduction The ECO-SHADOW Concept	1 1 1 1 1 1 1
17.2 17.3 17.4 17.5 18 18.1 18.2 18.3	of Human Pharmaceuticals III - Indirect Human Exposure Introduction Methodology Results Discussion Conclusions References The ECO-SHADOW Concept - A New Way of Following Environmental Impacts of Antimicrobials General Introduction The ECO-SHADOW Concept Influences of Antibiotics on Environmental Ecosystems	1 1 1 1 1 1 1 1
17.2 17.3 17.4 17.5 18 18.1 18.2 18.3	of Human Pharmaceuticals III - Indirect Human Exposure Introduction Methodology Results Discussion Conclusions References The ECO-SHADOW Concept - A New Way of Following Environmental Impacts of Antimicrobials General Introduction The ECO-SHADOW Concept	1 1 1 1 1 1 1 1

XVI Conte

Part	III Perspectives	
19	Present Knowledge and Need for Further Research 1	L
19.1	Detection of Pharmaceuticals in the Environment:	
	Substances and Concentrations	L
	19.1.1 Analytical Data	L
	19.1.2 Selection of Compounds to Be Analysed	L
19.2	Sources of Pharmaceuticals in the Environment	L
19.3	Fate of Pharmaceuticals in the Environment	
19.4	Effects of Pharmaceuticals in the Environment	
19.5	Risk	l
	19.5.1 Hazard Assessment	l
	19.5.2 Impact of Pharmaceuticals in the Environment	
	19.5.3 Risk Assessment	L
	19.5.4 Risk Management	l